<DOC>
	<DOCNO>NCT02762799</DOCNO>
	<brief_summary>BCD-002-1 1 phase clinical trial evaluate pharmacokinetics , pharmacodynamics safety single-injection Leucostim® healthy volunteer compare Neupogen®</brief_summary>
	<brief_title>Clinical Trial Evaluate Pharmacokinetics , Pharmacodynamics Safety Leucostim® Compared Neupogen®</brief_title>
	<detailed_description />
	<mesh_term>Leukocytosis</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Written inform consent . Male gender . Age 18 45 year . Normal body mass index . Verified diagnosis `` healthy '' , establish accord anamnesis , physical examination laboratory finding . Absence alcohol drug abuse . History use filgrastim . Allergy component study drug . Acute hemorrhage , donation blood / plasma blood transfusion last 2 month prior enrollment study , history chronic bleeding . Surgical intervention last 30 day prior screen plan surgical intervention study . Any disease could interfere pharmacokinetics filgrastim , include chronic liver , liver blood disease , disease cardiovascular , lung neuroendocrine system . Fever body temperature high 40°С .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>neutrophil count</keyword>
	<keyword>filgrastim</keyword>
	<keyword>granulocyte colony-stimulating factor</keyword>
</DOC>